(Q40344627)

19 September 2017

The cost-effectiveness of strategies to reduce mortality from an intentional release of aerosolized anthrax spores (English)

1 reference

19 September 2017

R Scott Braithwaite

1

1 reference

PubMed ID

16525172

19 September 2017

Douglas Fridsma

series ordinal

2

1 reference

PubMed ID

16525172

19 September 2017

Mark S Roberts

series ordinal

3

1 reference

19 September 2017

1 March 2006

1 reference

19 September 2017

Medical Decision Making

1 reference

19 September 2017

26

1 reference

19 September 2017

2

1 reference

19 September 2017

182-193

1 reference

The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable?

19 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Principles for emergency response to bioterrorism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Hospital preparedness for victims of chemical or biological terrorism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Accuracy of screening for inhalational anthrax after a bioterrorist attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Differentiating inhalational anthrax from other influenza-like illnesses in the setting of a national or regional anthrax outbreak.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Clinical predictors of bioterrorism-related inhalational anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Clinical and epidemiologic principles of anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Recognition and management of anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Clinical presentation of inhalational anthrax following bioterrorism exposure: report of 2 surviving patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Death due to bioterrorism-related inhalational anthrax: report of 2 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Automatic electronic laboratory-based reporting of notifiable infectious diseases at a large health system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

The informatics response in disaster, terrorism, and war.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

A two-component direct fluorescent-antibody assay for rapid identification of Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

An epidemic of inhalation anthrax, the first in the twentieth century: I. Clinical features. 1960.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Delayed life-threatening reaction to anthrax vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Analysis of adverse events after anthrax immunization in US Army medical personnel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Anthrax vaccination and self-reported symptoms, functional status, and medical conditions in the National Health Survey of Gulf War Era Veterans and Their Families

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Emergency response to an anthrax attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

Public health vaccination policies for containing an anthrax outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X06286794

21 January 2018

Identifiers

DOI

10.1177/0272989X06286794

1 reference

19 September 2017

1 reference

PubMed ID

16525172